Research programme: soluble angiotensin converting enzyme 2 protein therapeutics - Orthogonal Biologics
Latest Information Update: 03 Mar 2022
At a glance
- Originator University of Illinois
- Developer Orthogonal Biologics
- Class Antivirals; Recombinant fusion proteins
- Mechanism of Action Virus attachment inhibitors; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research COVID 2019 infections
Most Recent Events
- 22 Feb 2022 Early research in COVID-2019 infections in USA (unspecified route) as of February 2022 (Orthogonal Biologics website; February 2022)
- 23 Dec 2021 Soluble angiotensin converting enzyme 2 (ACE2) protein therapeutics licensed to Orthogonal Biologics as of December 2021
- 23 Dec 2021 Orthogonal Biologics has patent protection for use of engineered peptides targeting coronaviruses as of December 2021